000			03396nam a22004335i 4500
999			_c11282 _d11282
001			11282
003			DE-He213
005			20210706040346.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			180605s2018 gw | s |||| 0|eng d
020			_a9783319768793
024	7		_a10.1007/978-3-319-76879-3 _2doi
040			_aES-MaUEC _bspa _dES-VaUE
050		4	_aRC645.73 _b.M94 2018 EB
245	1	0	_aMyelodysplastic Syndromes: _bDiagnosis - Prognosis - Therapy _cedited by Uwe Platzbecker, Pierre Fenaux.
264		1	_aCham _bSpringer International Publishing : _bImprint: Springer _c2018.
300			_a1 recurso en línea (V, 157 páginas 26 ilustraciones, 22 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aHematologic Malignancies _x2197-9766
490	0		_aMedicine (Springer-11650)
505	0		_aDiagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation. .
520	3		_aThis book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.
988			_aEBSPRINGER_2018
650		7	_9140122 _aHematología
650		7	_aOncología _9139207
650		7	_aMédula ósea
700	1		_aPlatzbecker, Uwe. _eeditor literario
700	1		_aFenaux, Pierre. _eeditor literario _0http://id.loc.gov/authorities/names/no2014075471 _0http://viaf.org/viaf/74029040
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319768786
776	0	8	_iEdición impresa: _z9783319768809
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-76879-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0